Virtus Fund Advisers LLC trimmed its stake in Hill-Rom Holdings, Inc. (NYSE:HRC) by 3.8% in the 4th quarter, HoldingsChannel reports. The fund owned 1,122,526 shares of the medical technology company’s stock after selling 44,607 shares during the quarter. Hill-Rom comprises 0.9% of Virtus Fund Advisers LLC’s investment portfolio, making the stock its 21st largest position. Virtus Fund Advisers LLC’s holdings in Hill-Rom were worth $94,618,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Citigroup Inc. grew its stake in Hill-Rom by 21.1% during the 2nd quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock worth $198,000 after buying an additional 433 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in Hill-Rom by 101.0% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock worth $204,000 after buying an additional 1,367 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in Hill-Rom during the 3rd quarter worth $207,000. CAPROCK Group Inc. purchased a new position in Hill-Rom during the 4th quarter worth $211,000. Finally, Braun Stacey Associates Inc. purchased a new position in Hill-Rom during the 4th quarter worth $233,000. 80.84% of the stock is owned by hedge funds and other institutional investors.
In other news, CEO John J. Greisch sold 125,241 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $82.59, for a total value of $10,343,654.19. Following the sale, the chief executive officer now owns 280,851 shares in the company, valued at $23,195,484.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $82.99, for a total value of $82,990.00. Following the completion of the sale, the senior vice president now owns 1,066 shares in the company, valued at approximately $88,467.34. The disclosure for this sale can be found here. In the last quarter, insiders have sold 226,241 shares of company stock worth $18,708,644. Company insiders own 1.90% of the company’s stock.
Shares of Hill-Rom Holdings, Inc. (HRC) opened at $82.91 on Friday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.29 and a current ratio of 1.75. The firm has a market capitalization of $5,486.49, a PE ratio of 28.20, a price-to-earnings-growth ratio of 1.33 and a beta of 1.05. Hill-Rom Holdings, Inc. has a one year low of $63.02 and a one year high of $91.11.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings results on Friday, January 26th. The medical technology company reported $0.92 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.13. The business had revenue of $669.70 million for the quarter, compared to the consensus estimate of $670.00 million. Hill-Rom had a return on equity of 20.24% and a net margin of 7.14%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.75 EPS. equities research analysts forecast that Hill-Rom Holdings, Inc. will post 4.62 earnings per share for the current year.
HRC has been the topic of several research analyst reports. ValuEngine upgraded Hill-Rom from a “hold” rating to a “buy” rating in a research note on Thursday, November 16th. Stifel Nicolaus restated a “buy” rating and set a $92.00 target price on shares of Hill-Rom in a research note on Wednesday, November 29th. Needham & Company LLC dropped their price target on Hill-Rom from $93.00 to $90.00 and set a “buy” rating on the stock in a research note on Monday, November 6th. KeyCorp reiterated a “buy” rating and set a $89.00 price target (up previously from $82.00) on shares of Hill-Rom in a research note on Sunday, November 5th. Finally, Zacks Investment Research upgraded Hill-Rom from a “hold” rating to a “buy” rating and set a $90.00 price target on the stock in a research note on Friday, October 27th. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $95.38.
TRADEMARK VIOLATION WARNING: “Virtus Fund Advisers LLC Sells 44,607 Shares of Hill-Rom Holdings, Inc. (HRC)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/18/virtus-fund-advisers-llc-sells-44607-shares-of-hill-rom-holdings-inc-hrc.html.
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.